Articles from Mountain Valley MD Holdings Inc.

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTC: MVMDF) (FRA: 20MP) is pleased to provide an update on recent Agrarius™ agricultural product trial results, including key outcomes from its ongoing citrus field trials in Brazil and cattle pasture grass trials in Colombia. These trial programs are intended to support the Company’s customer product adoption strategy and commercial development initiatives for its licensed Agrarius agricultural plant signaling technology, designed to organically drive increased crop yields, reduce fertilizer and pesticide usage where desired, and enhance plant health.

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a business update on its commercialization progress across its three core areas of focus:

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce the appointment of David Batchelor to its board of directors.

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a 2024 year-end business update on its commercialization progress across its three core areas of focus:

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a general business update on its progress across its three core lines of business:

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce that it has executed an Amended and Restated Supply and License Agreement (the “Agreement”) with Agrarius Corp. (“AC”), a private US corporation, whereby it will, among other things, acquire an exclusive licence to AC’s agricultural plant signaling technology (the “Technology”) in North America, Mexico, South America, Central America, and the Caribbean (the “Exclusive Territory”), while retaining its global non-exclusive rights outside of the Exclusive Territory.

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), today announced the grant of stock options pursuant to its existing stock option plan (the “Stock Option Plan”).

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a broad business update of its progress across its three core lines of business:

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce the appointment of Yong Yao to the role of Chief Financial Officer effective January 15, 2024. The Company has accepted the resignation of the Company’s current Chief Financial Officer, Lucie Letellier, due to health issues that have resurfaced and require Ms. Letellier to take a leave of absence from her professional endeavours at this time. Ms. Letellier will continue to serve as the Company’s Chief Financial Officer until January 15, 2024 and assist with the transition to the new CFO.

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce the appointment of Lucie Letellier to the role of Chief Financial Officer effective September 11, 2023. Ms. Letellier succeeds Aaron Triplett, who previously served as Chief Financial Officer and will remain as a non-executive consultant of the Company through November 30, 2023 in order to ensure a seamless transition.

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a business update and details of its current progress.

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), a leading-edge publicly traded biotech company whose science includes that of novel solubilization methods for therapeutic compounds, is pleased to announce the recent peer-reviewed publication of the Company’s Soluvec™ study data in the journal, Therapeutic Delivery. The published study highlights the benefits of the Company’s patented Soluvec™ formulation, a novel, solvent-free aqueous Ivermectin invention. This proprietary Soluvec™ formulation was developed using the Company’s patented Quicksol™ solubilization technology, which aims to address the poor solubility challenges associated with Ivermectin and potentially other macrocyclic lactones.

TORONTO, May 08, 2023 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce that Mountain Valley MD Inc. (“Mountain Valley”) has entered into a license agreement (the “Agreement”) with a privately held Ontario corporation (the “Licensee”) for its Soluvec™1% animal husbandry applications for the territory of the People's Republic of Bangladesh.

TORONTO, March 06, 2023 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), an early-stage biotech business centered around the implementation, licensing and reselling of key technologies and formulations, today announced the grant of stock options pursuant to its existing stock option plan (the “Stock Option Plan”).

TORONTO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), an early-stage biotech business centered around the implementation, licensing and reselling of key technologies and formulations, today announced that Dr. Azhar Rana, the Company’s Chief Medical Officer (“CMO”), will be transitioning to an advisory capacity effective February 1, 2023.

TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) announces that it will redeem all issued and outstanding Class “B” Non-Voting Shares (the “Class B Shares”) of Mountain Valley MD Holdings Inc. (formerly Meadow Bay Gold Corp.). The Class B Shares are not listed for trading and are unrelated to the Company’s common shares, which trade on the Canadian Securities Exchange under the symbol “MVMD”.

TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a business update and details of its current commercialization strategy.